Future studies will determine if HDAC inhibition and DNMT inhibition can synergistically increase RGS10-1 expression, and define the role that RGS10 expression may play in the therapeutic effects of HDAC and DNMT inhibitors in ovarian cancer. The gene discussed is DNMT1; the disease is ovarian carcinoma.